{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:16:04Z","timestamp":1772151364636,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":288,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.rmcr.2025.102302","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T10:02:40Z","timestamp":1760695360000},"page":"102302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Regorafenib pulmonary toxicity: A case of cavitary lung disease and ARDS treated with infliximab"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2819-0208","authenticated-orcid":false,"given":"Michael","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mackenzie","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanmay","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.rmcr.2025.102302_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12328-019-00983-x","article-title":"Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma","volume":"12","author":"Kotani","year":"2019","journal-title":"Clin J Gastroenterol"},{"issue":"7","key":"10.1016\/j.rmcr.2025.102302_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed Death-1\/Programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2025.102302_bib3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2018.06.032","article-title":"Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC","volume":"123","author":"Suh","year":"2018","journal-title":"Lung Cancer"},{"issue":"2 D","key":"10.1016\/j.rmcr.2025.102302_bib4","article-title":"Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.rmcr.2025.102302_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101912","article-title":"Molecular insight of regorafenib treatment for colorectal cancer","volume":"81","author":"Arai","year":"2019","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.rmcr.2025.102302_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.707473","article-title":"Tyrosine kinase inhibitors stimulate HLA class I expression by augmenting the ifn\u03b3\/stat1 signaling in hepatocellular carcinoma cells","volume":"11","author":"Takahashi","year":"2021","journal-title":"Front. Oncol."},{"issue":"63","key":"10.1016\/j.rmcr.2025.102302_bib7","doi-asserted-by":"crossref","first-page":"107096","DOI":"10.18632\/oncotarget.22334","article-title":"Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma","volume":"8","author":"Kissel","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.rmcr.2025.102302_bib8","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1517\/17460441.2014.924923","article-title":"The preclinical development of regorafenib for the treatment of colorectal cancer","volume":"9","author":"Miura","year":"2014","journal-title":"Expet Opin. Drug Discov."},{"issue":"14","key":"10.1016\/j.rmcr.2025.102302_bib9","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1158\/1078-0432.CCR-18-2840","article-title":"Regorafenib promotes antitumor immunity via inhibiting PD-L1 and IDO1 expression in melanoma","volume":"25","author":"Wu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmcr.2025.102302_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114254","article-title":"Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-\u03b3\/NSDHL\/SREBP1\/TGF-\u03b21 axis in hepatocellular carcinoma","volume":"159","author":"Xie","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.rmcr.2025.102302_bib11","article-title":"Immunomodulatory effects of regorafenib: enhancing the efficacy of anti-PD-1\/PD-L1 therapy","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.rmcr.2025.102302_bib12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamaoncol.2022.7845","article-title":"Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial","volume":"9","author":"Fakih","year":"2023","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.rmcr.2025.102302_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.70286","article-title":"Regorafenib induced interstitial pneumonia in a patient with refractory rectal cancer","volume":"13","author":"Tsunoda","year":"2025","journal-title":"Respirol Case Rep"},{"issue":"1","key":"10.1016\/j.rmcr.2025.102302_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000486569","article-title":"A case of squamous cell carcinoma of unknown primary that responded to the multi-tyrosine kinase inhibitor lenvatinib","volume":"11","author":"Kimura-Tsuchiya","year":"2018","journal-title":"Case Rep. Oncol."},{"issue":"8","key":"10.1016\/j.rmcr.2025.102302_bib15","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2169\/internalmedicine.7300-21","article-title":"Lenvatinib-induced interstitial pneumonia in a patient with hepatocellular carcinoma","volume":"61","author":"Imakura","year":"2022","journal-title":"Intern Med"},{"key":"10.1016\/j.rmcr.2025.102302_bib16","article-title":"Pazopanib-induced organizing pneumonia in a patient with leiomyosarcoma: a case report","volume":"30","author":"Watanabe","year":"2020","journal-title":"Respir Med Case Rep"},{"issue":"7","key":"10.1016\/j.rmcr.2025.102302_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-235177","article-title":"Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma","volume":"13","author":"Harada","year":"2020","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.rmcr.2025.102302_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2169\/internalmedicine.56.7380","article-title":"Interstitial lung disease induced by pazopanib treatment","volume":"56","author":"Ide","year":"2017","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.rmcr.2025.102302_bib19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.5009\/gnl.2010.4.4.543","article-title":"Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report","volume":"4","author":"Myung","year":"2010","journal-title":"Gut Liver"},{"issue":"4","key":"10.1016\/j.rmcr.2025.102302_bib20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12328-012-0339-9","article-title":"Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases","volume":"5","author":"Takeda","year":"2012","journal-title":"Clin J Gastroenterol"},{"issue":"36","key":"10.1016\/j.rmcr.2025.102302_bib21","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.rmcr.2025.102302_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007409","article-title":"Corticosteroid-resistant immune-related adverse events: a systematic review","volume":"12","author":"Daetwyler","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.rmcr.2025.102302_bib23","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40264-016-0450-9","article-title":"Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas","volume":"39","author":"Shah","year":"2016","journal-title":"Drug Saf."},{"key":"10.1016\/j.rmcr.2025.102302_bib24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","article-title":"Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy","volume":"157","author":"Dimitriou","year":"2021","journal-title":"Eur. J. Cancer"}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007125001388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007125001388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:41:36Z","timestamp":1770972096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007125001388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":24,"alternative-id":["S2213007125001388"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2025.102302","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regorafenib pulmonary toxicity: A case of cavitary lung disease and ARDS treated with infliximab","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2025.102302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102302"}}